Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
-0.48% $2.09
America/New_York / 22 mar 2022 @ 00:00
FUNDAMENTALS | |
---|---|
MarketCap: | 177.42 mill |
EPS: | -0.260 |
P/E: | -8.04 |
Earnings Date: | May 04, 2022 |
SharesOutstanding: | 84.89 mill |
Avg Daily Volume: | 0.128 mill |
RATING 2022-05-23 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | n/a | n/a | ||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -8.04 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.17x |
Company: PE -8.04 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.998 - 2.18 ( +/- 4.40%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Lake Ryan David | Sell | 1 419 | Common Stock |
2023-12-15 | Lake Ryan David | Sell | 5 690 | Common Stock |
2023-11-30 | Lake Ryan David | Sell | 1 197 | Common Stock |
2023-10-31 | Lake Ryan David | Sell | 1 198 | Common Stock |
2023-09-30 | Lake Ryan David | Sell | 1 198 | Common Stock |
INSIDER POWER |
---|
94.59 |
Last 95 transactions |
Buy: 16 300 004 | Sell: 826 395 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.09 (-0.48% ) |
Volume | 0.138 mill |
Avg. Vol. | 0.128 mill |
% of Avg. Vol | 107.04 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.